drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Chimeric IgG1 monoclonal antibody (Qarziba) targeting GD2 on neuroblastoma cells; mediates ADCC (via NK cells and macrophages), complement-dependent cytotoxicity, and antibody-dependent phagocytosis; may also promote apoptosis.
nci_thesaurus_concept_id
C1570
nci_thesaurus_preferred_term
Dinutuximab
nci_thesaurus_definition
A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.
drug_mesh_term
Dinutuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Cytotoxic protein
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody targeting GD2 on neuroblastoma cells; induces tumor cell killing via Fc‑mediated ADCC (engaging NK cells and macrophages/monocytes), complement‑dependent cytotoxicity, and antibody‑dependent phagocytosis, with potential induction of apoptosis.
drug_name
Dinutuximab beta
nct_id_drug_ref
NCT06275334